

RESEARCH PLAN SUMMARY PAGE

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION,
RELEASE THIS SUMMARY PAGE TO THE PUBLIC.

TITLE OF RCA: Mechanistic insights into blood storage lesions and the development of antioxidant countermeasures

FDA Component: Center for Biologics Evaluation and Research (CBER)

FDA Principal Investigator: Abdu Alayash, Ph.D., D.Sc.

Collaborator: Vascarta Inc.

Collaborator Principal Investigator: Joel Friedman, M.D., Ph.D.

TERM OF RCA: Three (3) years from the Effective Date

ABSTRACT OF THE RESEARCH PLAN:

The parties would like to collaborate to study the pharmacodynamic properties of the curcumin topical/transdermal drug candidate on aged human blood cells through *in vitro* analysis. The goal of the project is to increase the shelf life and quality profile of refrigerated human blood which is potentially of huge impact to the field of transfusion medicine.